Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MD

This content originally appeared on our sister site, CancerNetwork®.

Data from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) of ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed/refractory multiple myeloma was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Philippe Moreau, MD, of the University Hospital of Nantes. CancerNetwork® spoke with Moreau regarding recent research in the field of multiple myeloma that may have a notable impact on the treatment paradigm. He discussed the promising results of cilita-cel.

Transcription:

At ASCO, we have [had] very important trials and very important results, especially for advanced patients. We have heard about the results of the CARTITUDE-1 trial, the updated analysis of the CAR T-cell therapy [cilta-cel from Janssen. The results seem really great in patients who are triple class refractory with a median progression-free survival that was not yet reached. [These were] very encouraging results. [There was] also a data analysis of bispecifics, such as teclistamab and talquetamab [JNJ-64407564] that was also very promising.

Reference

1. Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol 39, 2021 (suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004
2. Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021;39(suppl 15):8005. doi:10.1200/JCO.2021.39.15_suppl.8005